Premium
Cognitive–Behavioral Therapy for Insomnia in Knee Osteoarthritis: A Randomized, Double‐Blind, Active Placebo–Controlled Clinical Trial
Author(s) -
Smith Michael T.,
Finan Patrick H.,
Buenaver Luis F.,
Robinson Mercedes,
Haque Uzma,
Quain Angela,
McInrue Erin,
Han Dingfen,
Leoutsakis Jeannie,
Haythornthwaite Jennifer A.
Publication year - 2015
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.39048
Subject(s) - medicine , placebo , polysomnography , randomized controlled trial , insomnia , physical therapy , cognitive behavioral therapy for insomnia , osteoarthritis , sleep onset , cognitive behavioral therapy , clinical trial , anesthesia , psychiatry , apnea , alternative medicine , pathology
Objective Insomnia is prevalent among patients with knee osteoarthritis (OA). Research indicates that sleep disruption may amplify clinical pain by altering central pain modulation, suggesting that treatment of insomnia may improve pain. The aims of this study were to evaluate the efficacy of cognitive–behavioral therapy for insomnia (CBT‐I) in patients with knee OA, to determine whether improvements in sleep predict reduced pain, and to determine whether alterations in pain modulation mediate improvements in clinical pain. Methods We conducted a randomized, double‐blind, active placebo–controlled clinical trial of CBT‐I in 100 patients with knee OA and insomnia (mean ± SD age 59.4 ± 9.5 years). Patients were randomized (1:1) to receive either 8 sessions of CBT‐I or behavioral desensitization (placebo). We conducted in‐home polysomnography (PSG), diary assessment, and sensory tests of pain modulation at baseline, posttreatment, 3 months, and 6 months. Results Intent‐to‐treat analyses demonstrated substantial improvement in sleep in both groups of patients. Patients in the CBT‐I group had significantly greater reductions in wake after sleep onset (WASO), as measured by patient diary and PSG. Patients in both groups reported significant and comparable reductions in pain over 6 months, with one‐third reporting a 30% reduction in pain severity. Baseline‐to‐posttreatment reductions in WASO as measured by diary and PSG predicted subsequent decreases in clinical pain. This effect was significantly greater for CBT‐I compared with behavioral desensitization. No significant changes in laboratory measures of pain modulation were observed. Conclusion Compared with active placebo, CBT‐I was efficacious in reducing sleep maintenance insomnia. CBT‐I decreased clinical pain, but not pain modulation, suggesting that it has the potential to augment pain management in knee OA. Future work is needed to identify the mechanisms by which improved sleep reduces clinical pain.